PDCD1 and neoplasm: Stopping the interaction between the PD-1 protein and its ligand or PD-L1 with an inhibitory immune checkpoint (anti-PD-L1 or anti-PD-1) can stimulate anti-tumor activity, a phenomenon known as immune checkpoint blockade (ICB).